AVBP NASDAQ

Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), ArriVent BioPharma, Inc. would be worth roughly what it owes.
Total debt $351K against a stock market value of $759.3M.
Distance to default 8.74 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $176K (short-term plus half of long-term), stock volatility 91.5%; Altman Z'' 13.01. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.